Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revanceâs lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, delivering unprecedented efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. Source
No articles found.
California Labs has developed Loop, a connected personal display for the home. Loo...
California Labs has developed Loop, a connected...
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company...
VistaGen Therapeutics (NASDAQ: VTGN) is a clini...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Sierra Oncology is a clinical stage drug development company advancing targeted th...
Sierra Oncology is a clinical stage drug develo...
Landec Corporation (Nasdaq: LNDC) is a leading innovator of diversified health and...
Landec Corporation (Nasdaq: LNDC) is a leading ...
Join the National Investor Network and get the latest information with your interests in mind.